Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Buy Rating from Analysts at StockNews.com
StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) in a research note issued to investors on Thursday. The firm issued a buy rating on the biopharmaceutical company’s stock. Vanda Pharmaceuticals Trading Up 0.2 % NASDAQ:VNDA opened at $5.85 on Thursday. Vanda Pharmaceuticals has a 1 year low of $5.45 and a […]